Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Now Covered by Analysts at Guggenheim

Guggenheim began coverage on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in a research report released on Friday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $59.00 target price on the stock.

Several other analysts also recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. Wall Street Zen cut shares of Damora Therapeutics, Inc. Common Stock from a “hold” rating to a “sell” rating in a report on Saturday, October 31st. TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, August 24th. HC Wainwright reiterated a “buy” rating and set a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Finally, Jefferies Financial Group began coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They set a “buy” rating and a $50.00 price objective on the stock. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $46.38.

Damora Therapeutics, Inc. Common Stock Stock Performance

NASDAQ:DMRA traded up $1.84 during mid-day trading on Friday, hitting $23.70. 360,452 shares of the company’s stock traded hands, compared to its average volume of 448,096. The company has a fifty day moving average of $22.72 and a 200 day moving average of $25.70. Damora Therapeutics, Inc. Common Stock has a twelve month low of $4.95 and a twelve month high of $38.33. The company has a market capitalization of $1.46 billion, a P/E ratio of -7.03 and a beta of 1.52.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.12. On average, research analysts expect that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Damora Therapeutics, Inc. Common Stock news, CEO Jennifer Jarrett purchased 12,500 shares of the stock in a transaction on Friday, September 25th. The shares were bought at an average cost of $20.23 per share, with a total value of $252,875.00. Following the completion of the acquisition, the chief executive officer owned 512,500 shares in the company, valued at $10,367,875. This trade represents a 2.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.40% of the company’s stock.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Several institutional investors and hedge funds have recently modified their holdings of the stock. Arizona State Retirement System acquired a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter worth about $260,000. Squarepoint Ops LLC acquired a new position in Damora Therapeutics, Inc. Common Stock in the second quarter valued at approximately $303,000. Seven Fleet Capital Management LP purchased a new stake in Damora Therapeutics, Inc. Common Stock in the 2nd quarter worth approximately $7,398,000. Finally, Braidwell LP purchased a new stake in Damora Therapeutics, Inc. Common Stock in the 2nd quarter worth approximately $42,146,000. Institutional investors and hedge funds own 14.20% of the company’s stock.

Key Headlines Impacting Damora Therapeutics, Inc. Common Stock

Here are the key news stories impacting Damora Therapeutics, Inc. Common Stock this week:

• Positive Sentiment: Guggenheim initiated coverage with a Buy rating and a $59 price target, a notably bullish view that could bolster investor sentiment. Guggenheim analyst ratings
• Positive Sentiment: HC Wainwright maintained its Buy rating and $45 target despite trimming its forecasts, signaling continued confidence in the stock’s longer-term prospects. Damora Therapeutics analyst coverage
• Negative Sentiment: HC Wainwright lowered its EPS estimates across Q4 2026, all four quarters of 2027, FY2026 and FY2027. Its FY2027 loss estimate widened from $1.59 to $1.70 per share, suggesting weaker expected earnings and potentially weighing on sentiment. Damora Therapeutics analyst estimates

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.